Cardiol Therapeutics (CRDL) Competitors $1.08 +0.04 (+3.85%) Closing price 04:00 PM EasternExtended Trading$1.07 -0.01 (-0.93%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. DMAC, BNTC, LXEO, DBVT, IMAB, EDIT, ALTS, ANNX, AARD, and CGEMShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include DiaMedica Therapeutics (DMAC), Benitec Biopharma (BNTC), Lexeo Therapeutics (LXEO), DBV Technologies (DBVT), I-Mab (IMAB), Editas Medicine (EDIT), ALT5 Sigma (ALTS), Annexon (ANNX), Aardvark Therapeutics (AARD), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors DiaMedica Therapeutics Benitec Biopharma Lexeo Therapeutics DBV Technologies I-Mab Editas Medicine ALT5 Sigma Annexon Aardvark Therapeutics Cullinan Therapeutics Cardiol Therapeutics (NASDAQ:CRDL) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment. Which has preferable earnings and valuation, CRDL or DMAC? DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.18DiaMedica TherapeuticsN/AN/A-$24.44M-$0.69-10.22 Which has more risk and volatility, CRDL or DMAC? Cardiol Therapeutics has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Do analysts rate CRDL or DMAC? Cardiol Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 640.74%. DiaMedica Therapeutics has a consensus price target of $12.33, indicating a potential upside of 74.94%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00DiaMedica Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to CRDL or DMAC? In the previous week, Cardiol Therapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for DiaMedica Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.85 beat DiaMedica Therapeutics' score of 0.83 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CRDL or DMAC more profitable? DiaMedica Therapeutics' return on equity of -78.99% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -232.26% -158.19% DiaMedica Therapeutics N/A -78.99%-69.94% Do institutionals and insiders believe in CRDL or DMAC? 12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryCardiol Therapeutics beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.38M$2.96B$6.11B$10.46BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-3.1822.7985.3627.36Price / SalesN/A756.67607.16135.99Price / CashN/A172.6337.4661.86Price / Book4.915.5112.426.81Net Income-$26.77M$33.06M$3.32B$276.80M7 Day PerformanceN/A0.95%1.01%0.27%1 Month PerformanceN/A14.25%10.75%8.31%1 Year Performance-43.46%0.85%76.20%35.60% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics3.1023 of 5 stars$1.08+3.8%$8.00+640.7%-43.5%$89.38MN/A-3.1820News CoverageDMACDiaMedica Therapeutics2.0657 of 5 stars$6.93-2.0%$12.33+78.0%+53.6%$365.44MN/A-10.0420BNTCBenitec Biopharma1.8372 of 5 stars$13.66-1.3%$24.80+81.6%+48.2%$363.30MN/A-9.2920LXEOLexeo Therapeutics2.8073 of 5 stars$6.47-2.3%$15.33+137.0%+6.8%$357.49M$650K-1.9858Analyst ForecastDBVTDBV Technologies1.371 of 5 stars$13.29+3.0%$14.75+11.0%+347.8%$353.40MN/A-2.7980High Trading VolumeIMABI-Mab2.5309 of 5 stars$4.35+0.7%$7.33+68.6%+339.1%$352.77M$3.89M0.00380News CoverageGap UpEDITEditas Medicine4.2706 of 5 stars$3.80-3.1%$5.10+34.2%+10.8%$352.49M$38.90M-1.33230ALTSALT5 Sigma0.4871 of 5 stars$2.95+2.8%N/A+39.9%$351.89M$12.53M0.00170News CoveragePositive NewsANNXAnnexon2.5011 of 5 stars$3.18-0.3%$12.50+293.1%-59.5%$350.54MN/A-2.4760AARDAardvark Therapeutics4.3608 of 5 stars$17.05+6.0%$31.43+84.3%N/A$348.89MN/A0.0018Gap UpCGEMCullinan Therapeutics3.3193 of 5 stars$5.84-1.0%$26.00+345.2%-52.3%$348.54MN/A-1.8130News Coverage Related Companies and Tools Related Companies DMAC Alternatives BNTC Alternatives LXEO Alternatives DBVT Alternatives IMAB Alternatives EDIT Alternatives ALTS Alternatives ANNX Alternatives AARD Alternatives CGEM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
